Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018

Abstract

New cancer drugs approved by the FDA in 2018 would drastically increase cancer drug spending in the US if used widely. Alternatively, only low-level use of the new drugs is consistent with market forecasting.